Search

Your search keyword '"Chulanov, Vladimir"' showing total 270 results

Search Constraints

Start Over You searched for: Author "Chulanov, Vladimir" Remove constraint Author: "Chulanov, Vladimir"
270 results on '"Chulanov, Vladimir"'

Search Results

1. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial

2. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update

4. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

7. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

8. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D

9. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204

10. TOP-400 Impact of bulevirtide given with or without nucleos (t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection

11. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy

12. WED-395 Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta

13. LBP-029 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301

14. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial

15. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

16. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

17. The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution.

19. m6A Methylation in Regulation of Antiviral Innate Immunity

22. Swelling, Rupture and Endosomal Escape of Biological Nanoparticles Per Se and Those Fused with Liposomes in Acidic Environment.

27. m 6 A Methylation in Regulation of Antiviral Innate Immunity.

28. The burden of COVID-19 in a heterogeneous population of immunocompromised patients – realities of the postpandemic

29. P134 Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta: results from an interim analysis of a phase 3 randomized study

30. Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study

32. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

34. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

35. Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D

36. Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study

37. Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & HepatologyCommission update

38. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

39. Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9

41. Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle–Mimetic Nanovesicles Loaded with Chemotherapeutics

43. Treatment with Bulevirtide Improves Patient-reported Outcomes in Patients with Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks

44. Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results from a Phase 3 Randomized, Multicenter, Parallel Design Study

46. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia

47. Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle-Mimetic Nanovesicles Loaded with Chemotherapeutics

48. Genetic Diversity and Possible Origins of the Hepatitis B Virus in Siberian Natives

49. Diagnostic Capacities for Multidrug-Resistant Tuberculosis in the World Health Organization European Region

Catalog

Books, media, physical & digital resources